A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)

Trial Profile

A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Acalabrutinib (Primary) ; Rituximab (Primary) ; Ibrutinib
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 12 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 19 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top